1 July 2019
Coloplast – transactions in connection with share buy-back programme
As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 25 February, 2019 to 23 August, 2019.
The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.
The following transactions have been executed during the period 24 – 28 June 2019:
|Date||Number of shares||Buying price||Amount DKK|
|24 June 2019||6,974||749.55||5,227,360.31|
|25 June 2019||10,000||750.44||7,504,423.00|
|26 June 2019||4,734||748.13||3,541,652.15|
|27 June 2019||2,576||730.81||1,882,569.91|
|28 June 2019||12,000||741.81||8,901,675.60|
|Accumulated until now under the programme||557,680||711.84||396,981,588.64|
Henceforth, Coloplast owns 3,909,192 treasury B shares of DKK 1 equal to 1.81% of the company’s total share capital.
An overview showing the transaction data for the period 24 – 28 June 2019 is enclosed.
For further information, please contact
Investors and analysts
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 3376
Sr. Manager, Investor Relations
Tel. +45 4911 1800/ +45 4911 1786
Press and the media
Sr. Media Relations Manager
Tel. 4911 2607
This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ about 12,000 people.